|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Crown JP et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;[Epub ahead of print]. Abstract
Gennari A et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 2008;100(1):14-20. Abstract
Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract
Scaltriti M et al. Effect of lapatinib on accumulation of inactive HER2 at the cell membrane and on antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab: A novel mechanism for the enhanced effects of combined anti-HER2 therapy. Proc ASCO 2008;Abstract 3594.
Slamon D et al. Role of anthracycline-based therapy in the adjuvant treatment of breast cancer: Efficacy analyses determined by molecular subtypes of the disease. San Antonio
Breast Cancer Symposium 2007;Abstract 13.
Slamon D et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing cyclophosphamide followed by docetaxel (AC 
T) with doxorubicin and cyclophosphamide
followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. San Antonio Breast Cancer Symposium 2006;Abstract 52.
 |
 |
EDITOR
Neil Love, MD
INTERVIEWS
Nancy E Davidson, MD
- Select publications
Professor John Crown, MD
- Select publications
Kathy D Miller, MD
- Select publications
Peter M Ravdin, MD, PhD
- Select publications
THREE PERSPECTIVES ON US COOPERATIVE GROUP RESEARCH
Norman Wolmark, MD
- Select publications
Joyce O’Shaughnessy, MD
- Select publications
Eric P Winer, MD
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
